NRXP — NRX Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2017-12-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NRXP
| date | signal | measured base rate |
|---|---|---|
| 2026-05-26 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-05-15 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2024-12-17 | Javitt Jonathan C Chairman and Chief Scientist | Open-market purchase | 40.0K | 1.17 | 46.8K |
| 2023-08-30 | Hurvitz Chaim Director | Open-market purchase | 70.0K | 0.29 | 20.3K |
| 2023-08-30 | Gorovitz Aaron Director | Open-market purchase | 35.0K | 0.32 | 11.2K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| B Group, Inc. | 6.4M | 3.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | 1.2M |
| AdvisorShares Investments LLC | 895.6K | 420.5K |
| COMMONWEALTH EQUITY SERVICES, LLC | 846.5K | 397.4K |
| GEODE CAPITAL MANAGEMENT, LLC | 660.6K | 310.1K |
| VANGUARD FIDUCIARY TRUST CO | 361.2K | 169.6K |
| Bleakley Financial Group, LLC | 249.6K | 117.2K |
| BlackRock, Inc. | 210.9K | 99.0K |
| STATE STREET CORP | 185.3K | 87.0K |
| XTX Topco Ltd | 167.7K | 78.7K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-07 | 2026-08-07 | on EDGAR ↗ |
| 8-K | 2026-07-22 | 2026-07-21 | on EDGAR ↗ |
| 8-K | 2026-06-04 | 2026-06-03 | on EDGAR ↗ |
| 424B5 | 2026-06-03 | — | on EDGAR ↗ |
| 8-K | 2026-06-02 | 2026-06-02 | on EDGAR ↗ |
| 424B5 | 2026-06-02 | — | on EDGAR ↗ |
| 25-NSE | 2026-05-22 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- NRX Pharmaceuticals, Inc. (NRXP) filed form 8-K · 2026-08-17 · SEC EDGAR
- NRx Pharmaceuticals GAAP EPS of -$0.44, revenue of $1.1M · 2026-08-17
- NRX Pharmaceuticals, Inc. (NRXP) filed form 10-Q · 2026-08-14 · SEC EDGAR
Ask the AI about NRXP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →